Nault J.-C.ANN-LII CHENGSangro B.Llovet J.M.2021-08-312021-08-3120200168-8278https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076531556&doi=10.1016%2fj.jhep.2019.11.006&partnerID=40&md5=78057c57d3bb92d5021423330f4e9de8https://scholars.lib.ntu.edu.tw/handle/123456789/580035[SDGs]SDG3protein tyrosine kinase inhibitor; antineoplastic antimetabolite; protein kinase inhibitor; advanced cancer; bile duct carcinoma; cancer combination chemotherapy; cancer epidemiology; cancer immunotherapy; cancer surgery; cancer therapy; clinical assessment; Editorial; hepatography; human; liver carcinogenesis; liver cell carcinoma; liver transplantation; medical history; nonhuman; priority journal; radiation response; systemic therapy; adjuvant chemoradiotherapy; bile duct cancer; bile duct carcinoma; chemoembolization; immunotherapy; liver cell carcinoma; liver tumor; pathology; procedures; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Protein Kinase Inhibitorseditorial10.1016/j.jhep.2019.11.006319544862-s2.0-85076531556